Welcome to our spotlight on MSCs!
Quick access to all the content in the latest RegMedNet spotlight, including expert editorials, peer-reviewing journal content and more.
Since their isolation in the 1960s and 1970s, mesenchymal stem cells (MSCs) have been a popular target for regenerative therapies. The first clinical trial utilizing MSCs was complete in 1995 and over the past decade, there have been huge developments in our understanding of the method of action by which they can repair and regenerative tissue.
MSCs can be harvested from several human tissues, or derived from induced pluripotent stem cells (iPSCs), and can differentiate into a range of tissue-specific cells. Various studies have also shown the MSCs, unlike iPSCs, show few oncogenic properties, potentially making them safer as therapeutic agents. Their strong capacity for differentiation also makes MSCs useful as a tool to model disease progression and assess drug efficacy.
The spotlight will aim to review the current challenges in the production of MSCs with a focus on consistency, safety and efficacy. We will also look into the clinical applications of MSCs for regenerative medicine and how these therapies are going to evolve and change healthcare in the coming years.
Visit the spotlight - new posts weekly!
Editorials and interviews
- Developing iPSC-derived MSC-based therapies: an interview with Ross Macdonald, Cynata Therapeutics
- Coming soon: Stimulating regeneration with electrical stimulation: an interview with Sahba Mobini
- Counting keywords is not compiling clinical trials
- #TalkingRegMed: MSC bioprocessing with Alice Philipson, University of Leeds
- RegMedNet exclusive: Utilizing bone marrow-derived MSCs to repair bone defects: an interview with Miguel Forte
- RegMedNet exclusive: Utilizing MSCs for cardiac regeneration: an interview with Massimiliano Gnecchi
- Gene-modified mesenchymal stem cells as a potential treatment for Huntington's disease: preparing for a planned Phase I clinical trial
- Generation of inner ear sensory cells from bone marrow-derived human mesenchymal stem cells
- Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases
- Delivery of mesenchymal stem cells in biomimetic engineered scaffolds promotes healing of diabetic ulcers
- Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease
- Development of a biomaterial associated with mesenchymal stem cells and keratinocytes for use as a skin substitute
- A discussion on adult mesenchymal stem cells for drug delivery: pros and cons
- Treatment of perianal fistulas with human embryonic stem cell-derived MSCs: a canine model of human fistulizing Crohn's disease
- Limitless starting materials for large-scale manufacture of MSCs – what does the future hold?
- Controlled mechanotransduction in therapeutic MSCs: can remotely controlled magnetic nanoparticles regenerate bones?
- Cell therapy weekly: MSCs show promise to treat rare pediatric heart condition
- Stem cell treatment induces remission of Crohn’s disease-related perianal fistulas
- Is the wound healing potential of mesenchymal stem cells affected by cryopreservation?
- Chronic heart failure clinical trial: mesenchymal stem cell therapy safety & viability reported